“The good that comes from Cures Within Reach’s mission is incalculable in lives helped. Thanks for all you do to help people you will never know.”

Cancer Patient and Grant Review Committee Member Representing the Patient Voice
Cures Within Reach finds and funds clinical repurposing trials: testing approved therapies to fast-track safe and effective treatments for unsolved diseases.

Our patient-first approach focuses on generating early clinical data to de-risk and catalyze follow-on funding by others for larger, confirmatory trials, building the clinical evidence required for regulatory approval or off-label use.

2023 Achievements

- New organizational records:
  - **16** new clinical trials started with our funding: over two-thirds in rare diseases and over half in oncology, plus others in neurology, infectious diseases and more
  - **10** clinical trials successfully completed
  - **$16 million** raised by our funded researchers in follow-on funding for trials
- Strong growth in our key initiatives, with **13** more clinical trials selected to impact veterans, pediatrics, underrepresented patients and researchers
- Our first clinical trials selected in Benin, Tanzania and Uganda

At year-end, we had 42 ongoing clinical trials at 34 institutions in 30 diseases in 9 countries

Our Newest Success Story: Improving Outcomes in Tuberculosis

Tuberculosis (TB) remains a global health threat, causing over a million deaths annually. Current treatments require months-long antibiotic regimens, contributing to emerging drug resistance. In early 2023, Dr. Olanisun Olufemi Adewole at Obafemi Awolowo University in Nigeria published results of his pivotal Phase IIA clinical trial, adding atorvastatin to the standard of care for TB patients, showing that this safe, generic cholesterol-lowering drug may accelerate the clearance of the TB bacteria in patients when added to standard treatments. With this success, Dr. Adewole raised over $300,000 in follow-on funding from Open Philanthropy to support a larger confirmatory study. This could impact millions of patients.

This $50,000 pivotal trial provided data to support more than $300,000 in follow-on funding.

Together We’re Making Real Patient Impact

- **76** Diseases Researched
- **133** Projects Funded
- **85** Institutions Funded
- **21** Success Stories
- **$99 million** Follow-On Raised by Researchers
To Our Stakeholders:

From all of us at Cures Within Reach, it is my pleasure to share this summary of an exciting 2023. We remain energized by your continued commitment to our mission, and we are passionate about our fast-track impact on patients with unsolved diseases through repurposing: testing already approved therapies for new uses. We look forward to helping even more patients in 2024!

Please help us spread the word to impact more patients and more unsolved diseases by sharing this Annual Report and connecting us to funders and other partners in your network.

2023 Highlights:

- $16 million raised by our funded researchers in follow-on funding for trials
- Grew our ongoing portfolio to 42 clinical trials at year-end, including an organizational record of 16 new clinical trials started
- Selected our first clinical trials in Benin, Tanzania and Uganda
- Increased both the size and number of our clinical trial grants over last fiscal year
- Engaged more than 90 volunteer Grant Review Committee members, representing research, clinicians, industry and the patient/community voice
- Expanded our Diversity, Equity & Inclusion portfolio to include broader definitions of underrepresented patients and researchers in addition to race/ethnicity

We were thrilled to have Open Philanthropy join our growing list of major funding partners in 2023. In addition, we are excited about our expansion plans for community engagement funding alongside our clinical trials: in 2024 we’ll include our health disparities trials as well as other trials.

We are grateful for the physician scientists who share their repurposing ideas with us and move this work forward. We are grateful for the many patients in these clinical trials. We are grateful for our funding partners, community members and all our stakeholders. While this Annual Report features a few of our key partners, we are incredibly grateful for all who contributed to making 2023 a success!

Together we can improve the quality and length of life for patients faster through repurposing. They are counting on us.

Barbara Goodman
President & CEO
Cures Within Reach leverages the speed, safety and cost-effectiveness of repurposing, testing approved therapies for unsolved diseases: driving more treatments to more patients more quickly.

We find and fund proof-of-concept clinical trials of drugs, diagnostics, devices and nutraceuticals that, once successful, de-risk and catalyze follow-on funding for the larger, confirmatory trials, building the clinical evidence required for regulatory approval or to support off-label use by patients everywhere.

OUR MISSION

Creating Patient Impact: Staying Focused on “Why”
Cures Within Reach and our funding partners are passionate about impacting patients everywhere with unsolved diseases by developing “new” treatments using already approved therapies, known as repurposing. As a disease-agnostic, geography-agnostic, risk-mitigating catalyzer, our current portfolio covers a range of disease areas, from oncology and mental health to infectious diseases, rare diseases and inner ear disorders.

- 57% rare diseases
- 14% ear nose throat
- 38% oncology
- 19% neurology
- 12% infectious diseases
- 19% other
- 77% adult; 23% pediatric
- 86% drug; 14% device/other
- 81% US-based; 19% outside US
- 95% clinical; 5% pre-clinical

as of 12.31.2023

We are grateful for the support of our donors, sponsors, funding partners, funded researchers/institutions and patients in making these exciting clinical trials possible.
What we solve: **viable treatment options for patients in need**

We provide **seed funds to de-risk and unlock a catalytic effect**, building the **clinical evidence required** for regulatory approval or to support off-label use by patients everywhere.

Additive to Pharma Industry’s Life Cycle Management:
- Mid-stage: on-patent, but small indication or off-strategy
- Later stage: generic or new delivery method

CWR funding only when donor-directed
- CWR may consider funding at this stage

CWR funds human clinical trials when others say come back with proof-of-concept data
- CWR will fund at this stage

- Proof of Concept / Phase I
- CWR’s ideal funding
- Phase II: Leverage follow-on funding
- Little / No Commercial Value
- Likely / Known Commercial Value

Off-label use by clinicians via published, validated evidence
- Regulatory approval once therapeutic benefit is shown
Join us to bring treatment options to the millions who suffer with unsolved diseases. Our nearly 20-year successful track record in repurposing is complementary to lengthy de novo therapy research and has the potential to significantly reduce the time needed to reach as many patients as possible.

Philanthropy Focused on Speed-to-Impact
Together with our donor partners, we are de-risking new treatment options for patients, supporting researchers who have the clinical repurposing ideas to quickly reach patients everywhere.

- Donor partners choose their desired level of engagement in the design, search and selection process – our experienced team customizes the approach with you
- Grants starting at $60,000 and up to $250,000 can support a small, proof-of-concept human clinical trial or an expansion of an ongoing trial

Examples of Donor Partnerships:

<table>
<thead>
<tr>
<th>Donor</th>
<th>Goal</th>
<th>Involvement in Selection</th>
<th>2023 Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goldman Partnerships</td>
<td>Build pipeline to impact blood cancers</td>
<td>Foundation’s science advisor engaged with our 2-stage selection process</td>
<td>5 new blood cancer trials started in 2023</td>
</tr>
<tr>
<td>Becky and Lester Knight</td>
<td>Build broad pipeline for Meniere’s disease and related disorders</td>
<td>Very involved throughout our 2-stage selection process</td>
<td>Selected 2 more trials in 2023, adding to a portfolio of 9 completed or ongoing trials</td>
</tr>
<tr>
<td>Open Philanthropy</td>
<td>Tackle high disease burden in LMICs with readily available generics</td>
<td>Involved in up-front RFP design only</td>
<td>5 new LMIC-based clinical trials already started or will start in 2024</td>
</tr>
</tbody>
</table>

Partner with Us Today!

Spread the Word about Cures Within Reach to Help Reach the Millions of Patients with Unsolved Diseases

Our Value Proposition:

- An expert team providing bespoke services designed to meet your needs
- Technical expertise in finding, selecting, de-risking and managing our funded clinical trials
- Access to our vast global research network
- An efficient, proven RFP process, including external Grant Review Committee members representing research, industry, clinicians and the patient/community voice that support selection and strengthen trial protocols
- Project and financial progress reports both during and after the clinical trials

Donor-advised funding can support a specific disease, geography, patient population or other theme of donor’s choosing, such as:

- Impacting veterans’ issues
- In pediatrics
- In a specific disease area or geography
- Impacting health disparities
- Led by underrepresented researchers
13 New Clinical Trials Selected for Funding
During 2023, we had 6 funding opportunity Request for Proposals (RFPs): veterans; Meniere’s and related diseases; US health disparities; US-based underrepresented researchers; low and lower-middle income country (LMIC)-based researchers; and canine comparative. In addition to the 13 new clinical trials selected, these RFPs resulted in:

- 18% average funding rate from the 87 Letters of Intent submitted
- More than 90 volunteer Grant Review Committee members, representing research, clinicians, industry and the patient / community voice, supported our 2-stage process

Clinical Trials with Early Positive Evidence:
Symptoms improved and/or early positive evidence in chronic pediatric ear infections, Meniere’s disease, snakebite, traumatic brain injury and others, including publications/presentations

Follow-On Funding for Clinical Trials:
$16 million in new funding was reported during 2023 for ongoing clinical trials, next phase trials or related trials in tuberculosis, traumatic brain injury and snakebite, among others

Clinical Results Impacting Patients Everywhere:
Increased use of microbiotic FMT for pediatric C-difficile; increased use of PoNS for multiple sclerosis and stroke
### Disease Area | Institution | Title | Type | Community
--- | --- | --- | --- | ---
**Dermatology** | University of Antananarivo (Madagascar) | Effect of Methotrexate as a Treatment for Moderate to Severe Atopic Dermatitis in Madagascar | Drug, Adult | DEI, LMIC
**Infectious Disease, Rare** | International Centre for Diarrhoeal Disease Research (Bangladesh) | Assessing Safety and Efficacy of Oral Ivermectin in Post Kala-azar Dermal Leishmaniasis Treatment | Drug, Adult | Rare, DEI, LMIC
**Neurology** | University of California San Francisco | Testing the Epilepsy Drug Perampanel to Prevent Seizures After Cardiac Arrest * ^ | Drug, Adult | Neurology, DEI
**Neurology** | University of Zambia School of Medicine (Zambia) | Testing an Antihypertensive Drug as an Add-On Therapy for Drug-Resistant Epilepsy Patients in Zambia | Drug, Adult | Neurology, DEI, LMIC
**Neurology** | University of North Carolina Chapel Hill | Estrogen to Prevent Chronic Pain and PTSD Following Sexual Assault ^ | Drug, Adult | Neurology, DEI
**Oncology** | University of Illinois Chicago | Using a Generic Drug Combination in Early-Stage Hormone Receptor Positive Breast Cancer Patients ^ | Drug, Adult | Oncology, DEI, Chicago
**Oncology, Rare** | University of Pittsburgh | Investigating the Effects of a Rare Disease Drug in Treating AML and MDS Patients Who Have Relapsed Following Stem Cell Transplants | Drug, Adult | Oncology, Rare
**Oncology, Rare** | The University of Texas MD Anderson Cancer Center | Adding Metal Detoxification Drugs to Improve Childhood AML Outcomes | Drug, Pediatric | Oncology, Rare, Pediatric
**Oncology, Rare** | Emory University | Combining Approved Drugs for Alcoholism and Cancer to Treat Diffuse Large B-cell Lymphoma | Drug, Adult | Oncology, Rare
**Oncology, Rare** | Brown University / Rhode Island Hospital | Repurposing the Prostate Cancer Drug Degarelix to Treat Bladder Cancer * | Drug, Adult | Oncology, Rare, DEI
**Oncology, Rare** | City of Hope | Repurposing Venetoclax and Glofitamab to Improve Patient Response in Mantle Cell Lymphoma | Drug, Adult | Oncology, Rare, DEI
**Oncology, Rare** | Colorado State University | Evaluating an Approved Drug Combination plus Immunotherapy in Canine Metastatic Osteosarcoma | Drug, Preclinical | Oncology, Rare
**Oncology, Rare** | University of Michigan | Reducing CAR T-cell Therapy Complications in Relapsed Lymphoma Patients by Adding Natalizumab | Drug, Adult | Oncology, Rare
**Oncology, Rare** | Brigham Young University | Treating Anemia in Myelofibrosis with Nelfinavir | Drug, Adult | Oncology, Rare
**Rare** | Children's National Research Institute | Using Steroids to Improve Outcomes in Rhabdomyolysis in Pediatric Patients ^ | Drug, Pediatric | Rare, Pediatric, DEI, Mid-Atlantic
**Rare** | University of Chicago | Testing a Low-Dose Anti-inflammatory Tocilizumab for Acute Chest Syndrome in Sickle Cell Disease ^ | Drug, Adult | Rare, DEI, Chicago

* winner of CureAccelerator Live!
^ includes community engagement
# Ongoing Clinical Trials in 2023

26 trials at 25 institutions in 21 diseases in 4 countries

<table>
<thead>
<tr>
<th>Disease Area</th>
<th>Institution</th>
<th>Title</th>
<th>Type</th>
<th>Community</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autoimmune</td>
<td>Massachusetts General Hospital</td>
<td>Repurposing a Vaccine for Type I Diabetes</td>
<td>Vaccine, Adult</td>
<td>General</td>
</tr>
<tr>
<td>Ear Nose Throat</td>
<td>Dent Neurologic Institute</td>
<td>Combining an Anti-epileptic Drug with an Anti-anxiety Drug to Treat the Inner Ear Disorder Meniere’s Disease</td>
<td>Drug, Adult</td>
<td>General</td>
</tr>
<tr>
<td>Ear Nose Throat</td>
<td>House Institute Foundation</td>
<td>Reducing Vertigo and Hearing Loss in Meniere’s Disease by Repurposing a Common Allergy Drug</td>
<td>Drug, Adult</td>
<td>General</td>
</tr>
<tr>
<td>Ear Nose Throat</td>
<td>ibs.GRANADA (Spain)</td>
<td>Searching for Pharmacogenetic Targets in Meniere’s Disease Patients</td>
<td>Diagnostic, Preclinical</td>
<td>General</td>
</tr>
<tr>
<td>Ear Nose Throat</td>
<td>Hospital of the Ludwig-Maximilians University (Germany)</td>
<td>Identifying a Potential Biomarker and Repurposed Migraine Treatment in Meniere’s Disease</td>
<td>Drug, Adult</td>
<td>General</td>
</tr>
<tr>
<td>Immune Disorder, Rare</td>
<td>St. Jude Children’s Research Hospital</td>
<td>Repurposing a Blood Cancer Drug to Treat an Immune Disorder (HLH) in Children *</td>
<td>Drug, Pediatric</td>
<td>Rare, Pediatric</td>
</tr>
<tr>
<td>Immune Disorder, Rare</td>
<td>Cincinnati Children’s Hospital Medical Center</td>
<td>Repurposing a Rare Disease Treatment for the Immune Disorder Eosinophilic Esophagitis</td>
<td>Drug, Adult</td>
<td>Rare, DEI</td>
</tr>
<tr>
<td>Infectious Disease</td>
<td>George Washington University, Universidad El Bosque</td>
<td>Repurposing a Flu Treatment for Severe Dengue Patients in Colombia</td>
<td>Drug, Pediatric</td>
<td>Pediatric, Mid-Atlantic, LMIC, DEI</td>
</tr>
<tr>
<td>Infectious Disease</td>
<td>University of Chicago</td>
<td>Can Vitamin D Reduce the Burden of COVID-19 in Chicago?</td>
<td>Nutraceutical, Adult</td>
<td>Chicago, DEI</td>
</tr>
<tr>
<td>Infectious Disease, Ear Nose Throat, Rare</td>
<td>University of Utah</td>
<td>Repurposing the Antiviral Drug Valganciclovir to Treat Cytomegalovirus-induced Hearing Loss</td>
<td>Drug, Pediatric</td>
<td>Rare, Pediatric</td>
</tr>
<tr>
<td>Inflammatory Disease</td>
<td>SIDS Hospital and Research Centre (India)</td>
<td>Combining the Cholesterol-Lowering Drug Simvastatin with N-Acetylcysteine for Chronic Pancreatitis in India</td>
<td>Drug, Adult</td>
<td>DEI, LMIC</td>
</tr>
<tr>
<td>Neurology</td>
<td>Rush University Medical Center</td>
<td>Enhancing PTSD Treatment For Veterans Via Prebiotic Supplementation</td>
<td>Nutraceutical, Adult</td>
<td>Neurology, Veterans, Chicago</td>
</tr>
<tr>
<td>Neurology</td>
<td>University of California, Los Angeles</td>
<td>Testing a Repurposed Device to Improve the Treatment of Chronic Pelvic Pain in Women</td>
<td>Device, Adult</td>
<td>Neurology, DEI</td>
</tr>
<tr>
<td>Neurology</td>
<td>Edward Hines Jr VA Hospital and CARES</td>
<td>Using an Approved Depression Treatment to Restore Cognitive Function in Veterans with Mild TBI and PTSD</td>
<td>Device, Adult</td>
<td>Neurology, Veterans, Chicago</td>
</tr>
<tr>
<td>Neurology</td>
<td>Advocate Aurora Health</td>
<td>Testing a Low-Dose of the Hypertension Drug Clonidine for PTSD in Veterans</td>
<td>Drug, Adult</td>
<td>Neurology, Veterans</td>
</tr>
<tr>
<td>Neurology, Infectious Disease</td>
<td>Emory University School of Medicine</td>
<td>Addressing Chronic Pain in HIV Patients with an Approved Addiction Treatment ^</td>
<td>Drug, Adult</td>
<td>Neurology, DEI</td>
</tr>
<tr>
<td>Oncology, Rare</td>
<td>Children’s Hospital of Philadelphia</td>
<td>Preventing Relapse After Bone Marrow Transplant in Pediatric Acute Lymphoblastic Leukemia with a Personalized Treatment</td>
<td>Drug, Pediatric</td>
<td>Rare, Oncology, Pediatric, Mid-Atlantic</td>
</tr>
<tr>
<td>Oncology, Rare</td>
<td>University of California, Irvine</td>
<td>Treating a Group of Rare Blood Cancers, Myeloproliferative Neoplasms, with N-acetylcysteine *</td>
<td>Drug, Adult</td>
<td>Oncology, Rare</td>
</tr>
<tr>
<td>Oncology, Rare</td>
<td>University of Michigan</td>
<td>Repurposing Old Drugs As New Therapies for Metastatic Thyroid Cancer *</td>
<td>Drug, Adult</td>
<td>Oncology, Rare</td>
</tr>
<tr>
<td>Oncology, Rare</td>
<td>Loyola University of Chicago</td>
<td>Repurposing the Blood Pressure Drug Minoxidil for the Treatment of Recurrent Chemo-resistant Ovarian Cancer</td>
<td>Drug, Adult</td>
<td>Oncology, Rare, Chicago</td>
</tr>
<tr>
<td>Oncology, Rare</td>
<td>The University of Texas MD Anderson Cancer Center</td>
<td>Enhancing Treatment Response in Recurrent / Metastatic Osteosarcoma with Hydroxychloroquine *</td>
<td>Drug, Pediatric</td>
<td>Rare, DEI, Oncology, Pediatric</td>
</tr>
<tr>
<td>Oncology, Rare</td>
<td>University College Hospital Ibadan (Nigeria)</td>
<td>Adding the Antibiotic Clofazimine to Chemotherapy for Triple Negative Breast Cancer in Nigeria</td>
<td>Drug</td>
<td>Oncology, Rare, DEI, LMIC</td>
</tr>
<tr>
<td>Oncology, Rare</td>
<td>University of Illinois Chicago</td>
<td>Repurposing a Diagnostic Device to Address Health Disparities in Esophageal Cancer Screening and Outcomes ^</td>
<td>Device-Diagnostic, Adult</td>
<td>Rare, DEI, Chicago, Oncology</td>
</tr>
<tr>
<td>Ophthalmology, Rare</td>
<td>University of Michigan</td>
<td>Testing a Generic Malaria Drug in a Rare Ophthalmic Condition</td>
<td>Drug, Adult</td>
<td>Rare</td>
</tr>
<tr>
<td>Rare</td>
<td>Stanford University</td>
<td>Treating Vascular Malformations Using the Cancer Drug Targeting *</td>
<td>Drug, Pediatric</td>
<td>Rare, Pediatric</td>
</tr>
<tr>
<td>Rare</td>
<td>Vietnam National Children’s Hospital / Big Leap Research (Vietnam)</td>
<td>Improving Outcomes for the Rare Liver Disease Biliary Atresia With a Cancer Drug</td>
<td>Drug, Pediatric</td>
<td>Rare, DEI, LMIC</td>
</tr>
</tbody>
</table>

* winner of CureAccelerator Live!
^ includes community engagement
### CLINICAL TRIALS COMPLETED IN 2023

**10 trials at 10 institutions in 8 diseases in 4 countries**

<table>
<thead>
<tr>
<th>Disease Area</th>
<th>Institution</th>
<th>Name</th>
<th>Type</th>
<th>Community</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Autoimmune, Ophthalmology</strong></td>
<td>Northwestern University</td>
<td>Treating Cataracts In Diabetic Patients Using a Surgical Device</td>
<td>Device, Adult</td>
<td>Chicago</td>
</tr>
<tr>
<td><strong>Ear Nose Throat</strong></td>
<td>Feinstein Institutes for Medical Research</td>
<td>Investigating the Effects of Repurposed Diuretic, Steroid and Immunosuppressive Drugs in Meniere's Disease</td>
<td>Drug, Preclinical</td>
<td>General</td>
</tr>
<tr>
<td><strong>Ear Nose Throat</strong></td>
<td>Medical University of South Carolina</td>
<td>Assessing the Efficacy of an Antidepressant for Improving Vertigo Attacks in Meniere's Disease</td>
<td>Drug, Adult</td>
<td>General</td>
</tr>
<tr>
<td><strong>Ear Nose Throat</strong></td>
<td>Hospital of the Ludwig-Maximilians University (Germany)</td>
<td>Combining a Vertigo Drug With a Parkinson's Disease Drug to Treat the Inner Ear Disorder, Meniere's Disease</td>
<td>Drug, Adult</td>
<td>General</td>
</tr>
<tr>
<td><strong>Ear Nose Throat, Infectious Disease</strong></td>
<td>University College Hospital Ibadan (Nigeria)</td>
<td>Repurposing a Widely Available Antiseptic in Pediatric Chronic Ear Infections in Nigeria</td>
<td>Drug, Pediatric</td>
<td>DEI, LMIC, Pediatric</td>
</tr>
<tr>
<td><strong>Neurology</strong></td>
<td>University of New Mexico</td>
<td>Repurposing N-Acetylcysteine to Reduce Oxidative Stress, an Important Factor in Traumatic Brain Injury</td>
<td>Drug, Adult</td>
<td>Veterans, Neurology</td>
</tr>
<tr>
<td><strong>Neurology, Rare</strong></td>
<td>The University of Texas Health Science Center at Houston</td>
<td>Treating Irritability in Huntington's Disease With a Repurposed Neurological Drug</td>
<td>Drug, Adult</td>
<td>Neurology, Rare</td>
</tr>
<tr>
<td><strong>Oncology, Rare, Neurology</strong></td>
<td>Massachusetts General Hospital / Harvard</td>
<td>A Novel Combination of Generic Chemotherapy Drugs to Treat Brain Cancer</td>
<td>Drug, Adult</td>
<td>Rare, Oncology, Neurology</td>
</tr>
<tr>
<td><strong>Ophthalmology, Rare</strong></td>
<td>University of California, Davis</td>
<td>Repurposing Bone Marrow Stem Cell Therapy for Vision Loss Caused by Retinitis Pigmentosa</td>
<td>Other, Adult</td>
<td>Rare</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>KEMRI-Wellcome Trust Research Programme (Kenya)</td>
<td>Testing The Safety of a Metal Poisoning Drug to Treat Snakebite</td>
<td>Drug, Adult</td>
<td>DEI, LMIC</td>
</tr>
<tr>
<td>Disease Area</td>
<td>Institution</td>
<td>Title</td>
<td>Type</td>
<td>Community</td>
</tr>
<tr>
<td>----------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>Ear Nose Throat</td>
<td>Yale University</td>
<td>Investigating the Effects of Blocking Immune Disease Pathways in Meniere’s Disease</td>
<td>Drug, Preclinical</td>
<td>General</td>
</tr>
<tr>
<td>Ear Nose Throat</td>
<td>University Hospital of Munich</td>
<td>Treating Vestibular Neuritis Symptoms with a Thyroid Hormone</td>
<td>Drug, Adult</td>
<td>General</td>
</tr>
<tr>
<td>Infectious Disease</td>
<td>Université d'Abomey-Calavi (Benin)</td>
<td>Adding Beta-lactam Antibiotics to Shorten Buruli Ulcer Disease Therapy in Benin</td>
<td>Drug, Adult and Pediatric</td>
<td>DEI, Pediatric, LMIC</td>
</tr>
<tr>
<td>Inflammatory Disease</td>
<td>University of Illinois Chicago</td>
<td>Topical Probiotic Sinus Irrigations for the Treatment of Chronic Rhinosinusitis: A Randomized Controlled Trial</td>
<td>Drug, Adult</td>
<td>Chicago, DEI</td>
</tr>
<tr>
<td>Maternal Health</td>
<td>Busitema University (Uganda)</td>
<td>Using Sodium Bicarbonate to Reduce Maternal / Fetal Death from Acidosis During Obstructed Labor in Uganda</td>
<td>Drug, Adult and Pediatric</td>
<td>DEI, Pediatric, LMIC</td>
</tr>
<tr>
<td>Neurology</td>
<td>Virginia Commonwealth University</td>
<td>Daily Rotigotine Patch to Enhance Behavioral Therapy for Cocaine Use Disorder Recovery in Veterans</td>
<td>Drug, Adult</td>
<td>Veterans, Neurology, Mid-Atlantic</td>
</tr>
<tr>
<td>Neurology</td>
<td>Edward Hines Jr VA Hospital and CARES</td>
<td>Improving Cognitive Function in Veterans with Atypical Parkinsonism with rTMS Brain Stimulation</td>
<td>Device, Adult</td>
<td>Veterans, Neurology, Chicago</td>
</tr>
<tr>
<td>Neurology</td>
<td>University of Illinois Chicago</td>
<td>Adding an Antihistamine to Improve Outcomes in Depression</td>
<td>Drug, Adult</td>
<td>Neurology, DEI, Chicago</td>
</tr>
<tr>
<td>Oncology</td>
<td>University of Colorado Anschutz Medical Campus</td>
<td>Reducing Side Effects of Breast Cancer Treatments with Oxytocin</td>
<td>Drug, Adult</td>
<td>Oncology, DEI</td>
</tr>
<tr>
<td>Oncology</td>
<td>University of Illinois Chicago</td>
<td>Glycyrrhizin in Prostate Cancer: A Window-of-Opportunity Clinical Trial</td>
<td>Nutraceutical, Adult</td>
<td>Oncology, Chicago, DEI</td>
</tr>
<tr>
<td>Oncology</td>
<td>University of Pittsburgh</td>
<td>Reducing Immune-Related Adverse Events by Adding Oral FMT to Solid Tumor Cancer Treatment</td>
<td>Other, Adult</td>
<td>Oncology, DEI</td>
</tr>
<tr>
<td>Oncology, Rare</td>
<td>Muhimbili University Health and Allied Sciences (Tanzania)</td>
<td>Testing a Generic Drug Combination to Treat AML in Tanzania</td>
<td>Drug, Adult</td>
<td>Oncology, Rare, DEI, LMIC</td>
</tr>
<tr>
<td>Rare</td>
<td>Global Health Uganda</td>
<td>Adding Zinc to Reduce Sickle Cell Anemia-related Infections in Ugandan Children</td>
<td>Nutraceutical, Pediatric</td>
<td>DEI, Pediatric, LMIC</td>
</tr>
</tbody>
</table>

“The proposals that I reviewed make me a believer in CWR – thank you for what you do.”

Global Health Expert and Grant Review Committee Member from FHI Clinical
In 2023, we continued building our 9 communities that align with our stakeholders’ strategic interests:

- **Disease-specific**: Rare Diseases; Oncology; and Neurology (including neurodegenerative, mental health, pain)
- **Populations**: Pediatrics; Veterans/Military; and Diversity, Equity & Inclusion
- **Geographic**: Chicago; Mid-Atlantic; and Low and Lower-Middle Income Countries

Most of our trials overlap communities. For example, our ongoing clinical trial in pediatric osteosarcoma impacts our Pediatrics, Oncology, Rare Diseases and DEI communities.

These virtual communities engage key stakeholders with an aligned goal: bring viable treatment options to patients with unsolved diseases wherever they live.
After launching our Veterans Initiative in 2020, our growing portfolio now has 3 ongoing trials, 3 completed trials plus 2 more selected in 2023.

The 2 new clinical trials starting in 2024 are:

- Daily Rotigotine Patch to Enhance Behavioral Therapy for Cocaine Use Disorder Recovery in Veterans at Virginia Commonwealth University
- Improving Cognitive Function in Veterans with Atypical Parkinsonism with rTMS Brain Stimulation at Edward Hines Junior VA Hospital / CARES in Chicago

Of our 42 ongoing trials at year-end, 3 are in Veterans / Military

Our Pediatrics Community launched in 2021 and our growing portfolio now has 9 ongoing trials, 7 recently completed trials plus 3 more selected in 2023.

The 3 new clinical trials starting in 2024 are:

- Using Sodium Bicarbonate to Reduce Maternal / Fetal Death from Acidosis During Obstructed Labor in Uganda at Busitema University
- Adding Zinc to Reduce Sickle Cell Anemia-related Infections in Ugandan Children at Global Health Uganda
- Adding Beta-lactam to Shorten Buruli Ulcer Disease Therapy in Benin at Université d'Abomey-Calavi

Of our 42 ongoing trials at year-end, 9 are in Pediatrics
In 2023, we continued building our portfolio in US-based Diversity, Equity & Inclusion (DEI) with funding opportunity RFPs seeking clinical trials to address health disparities and/or led by underrepresented researchers in any disease. We also now use the broader definitions of underrepresented patients and researchers in addition to race/ethnicity.

- 26 Letters of Intent received from 13 US states/DC; 10 invited to submit full proposal applications
- 29 Grant Review Committee members recruited (representing research, clinicians, industry and the patient/community voice), including more than 50% BIPOC members

4 new clinical trials were selected for funding in 2023, including 3 in health disparities with community-based organization engagement alongside the trial:

- Reducing Side Effects of Breast Cancer Treatments with Oxytocin at University of Colorado (underrepresented researcher)
- Adding an Antihistamine to Improve Outcomes in Depression at University of Illinois Chicago (underrepresented researcher; health disparities trial with community engagement)
- Glycyrrhizin in Prostate Cancer: A Window-of-Opportunity Clinical Trial at University of Illinois Chicago (underrepresented researcher; health disparities trial with community engagement)
- Reducing Immune-Related Adverse Events by Adding Oral FMT to Solid Tumor Cancer Treatment at University of Pittsburgh (health disparities trial with community engagement)
In 2023, not only did 3 new LMIC-based trials begin in Bangladesh, Madagascar and Zambia and 3 trials completed, but we also held our 4th Request for Proposals for clinical trials led by LMIC-based researchers in any disease.

- 35 Letters of Intent received from 17 countries, including first time submissions from Benin, Ethiopia and Zimbabwe; 9 invited to submit full proposal applications
- 33 Grant Review Committee members recruited, representing research, clinicians, industry, philanthropy, the patient voice and the global health community

4 new clinical trials were selected for funding in 2023:
- Using Sodium Bicarbonate to Reduce Maternal / Fetal Death from Acidosis During Obstructed Labor in Uganda at Busitema University
- Testing a Generic Drug Combination to Treat AML in Tanzania at Muhimbili University Health and Allied Sciences
- Adding Zinc to Reduce Sickle Cell Anemia-related Infections in Ugandan Children at Global Health Uganda
- Adding Beta-lactam to Shorten Buruli Ulcer Disease Therapy in Benin at Université d'Abomey-Calavi

Our Newest Success Story: Improving Outcomes in Tuberculosis

Tuberculosis remains a global health threat, causing over a million deaths annually. Current treatments require months-long antibiotic regimens, contributing to emerging drug resistance. In early 2023, Dr. Olanisun Olufemi Adewole at Obafemi Awolowo University in Nigeria published results of his pivotal Phase IIA clinical trial, adding atorvastatin to the standard of care for tuberculosis patients, showing that this safe, generic cholesterol-lowering drug may accelerate the clearance of the TB bacteria in patients when added to standard treatments. With this success, Dr. Adewole has received over $300,000 in follow-on funding from Open Philanthropy to support a larger confirmatory study. This could impact millions of patients.

This $50,000 pivotal trial provided data to support more than $300,000 in follow-on funding.
COMMUNITY ENGAGEMENT

Since 2020, all of our clinical trials impacting health disparities require the engagement of community-based organizations alongside the trials. Including social services organizations, community health and other healthcare nonprofits, and faith-based groups, this community engagement component (funded in partnership with Burroughs Wellcome Fund and others) strengthens our clinical trials through better inclusion of underrepresented communities and patients throughout the entire clinical process – before the trial begins enrollment, during the study, as well as supporting post-trial dissemination of the results.

We hold community engagement training sessions for our funded researchers and clinical teams. In addition, a Lead Engagement Consultant is available to support our funded researchers, clinical teams and institutions as they plan and implement the trials’ community engagement activities.

To date, we have 7 ongoing health disparities trials with this additional community engagement, plus 3 selected that should start in 2024. In addition, in 2024 we are expanding this beyond health disparities to include other trials.

OTHER DEVELOPMENTS

In addition to the inclusion of community engagement alongside our clinical trials, there are several other developments impacting patient treatment options that we are actively supporting. Each will have a positive on our mission in 2024, and include:

• Adding real world evidence and natural history as control arms, building upon data robustness of randomized control trials
• The impact of FDA guidance on integrating Diversity, Equity, and Inclusion principles in clinical trials for compliance and to enhance the quality and relevance of clinical research
• European initiatives to facilitate label extensions for generic drugs to enhance patient adoption
• Using artificial intelligence / machine learning as a predictor for clinical trials to impact patients everywhere
• Cell and gene therapies and related technologies as more are FDA-approved and become eligible for our funding
Our 2023 annual golf fundraiser, held again at Rich Harvest Farms, raised more than $50,000 towards our mission.

A portion of the proceeds helped fund new clinical trials impacting pediatrics and veterans.

Thanks to our event Co-Chairs Steve Goodfriend and Bobby Miller, and to our many golfers raising funds.

Thanks also to our event sponsors:
Goldman Philanthropic Partnerships, Judy Hirsch Foundation, M&M Bank, Aaron Domash’s foursome and Peter Kupferberg’s foursome
**BY THE NUMBERS**

<table>
<thead>
<tr>
<th>Income By Source (FY2023)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Private Foundations, 81%</td>
</tr>
<tr>
<td>Individuals, 16%</td>
</tr>
<tr>
<td>Healthcare Industry, 2%</td>
</tr>
<tr>
<td>Other, 1%</td>
</tr>
</tbody>
</table>

**Clinical Trial Funding Awarded**

- FY2018: $0,000
- FY2019: $200,000
- FY2020: $400,000
- FY2021: $600,000
- FY2022: $800,000
- FY2023: $1,000,000

**BY GEOGRAPHY**

In addition to the 34 ongoing clinical trials across the US, our ongoing trials are also in:

- Bangladesh
- Germany
- India
- Madagascar
- Nigeria
- Spain
- Vietnam
- Zambia

*as of 12.31.2023*
OUR LEADERSHIP

Board of Directors
Margaret Christie, JD, *Chair*, Golan Christie Taglia LLP
Lucy Mancini-Newell, *Secretary*, Consultant
Matthew Rich, *Treasurer*, PwC
Kristina Allikmets, MD, PhD, Takeda
Steve Braun, Northwestern Mutual
Nick Manusos, Ryne Biotechnology and MagSeven LLC
Robert Metz, Armour Life Sciences
David Styler, Amgen / Horizon Therapeutics
Nancy Sullivan, IllinoisVENTURES llc

Science Advisory Board
Jeff Sherman, MD, *Chair*, Amgen / Horizon Therapeutics *(retired)*
Andrés Klein, PhD, *Vice-Chair*, Universidad del Desarrollo
Kevin B. Clark, PhD, *Past Chair*, Consultant to NASA/NSF/others
Luis Caveda, PhD, LFB USA
Tim Cunniff, PharmD, Paragon Pharmaceuticals
Douglas Feinstein, PhD, University of Illinois Chicago
Shuli Kulak, MD, Solid Biosciences
Murray Lumpkin, MD, MSc, Bill & Melinda Gates Foundation
Wilfred Ngwa, PhD, MSc, Johns Hopkins University
Larry Sklar, PhD, University of New Mexico
Vidula Sukhatme, MS, GlobalCures and Emory University

Business Development / Commercialization Committee
Adam Elhoyf, PhD, Cour Pharmaceutical
Ed Kahn, Rediscovery Life Sciences
Robert Metz, Armour Life Sciences
Norbert Riedel, PhD, Board Member of Jazz Pharmaceuticals, Eton Pharmaceuticals and Cerevel
Michael S. Rosen, Rosalind Franklin University and Rosen BioScience Strategies
Adriann Sax, Vetigenics
Eric Waehner, Recordati Rare Diseases

Cures Within Reach
Barbara Goodman, President & CEO
Clare Thibodeaux, PhD, Vice President, Scientific Affairs
Juliet Rowe, Program Manager

*plus invaluable support from additional staff, interns and consultants*

We are also grateful for the support from
over 90 volunteer Grant Review Committee Members
who reviewed, ranked and scored over 85 LOIs and over 20 full proposals throughout 2023.